MyFinsight
Home
Blog
About
Proceeds from sale of
common stock pursuant...
$10,000K
Proceeds from sale of
common stock pursuant...
$120K
(-96.45%↓ Y/Y)
Net cash provided by
financing activities
$9,390K
(202.12%↑ Y/Y)
Canceled cashflow
$730K
Net increase
(decrease) in cash and cash...
$1,883K
(122.80%↑ Y/Y)
Canceled cashflow
$7,507K
Payment of offering
costs
$730K
(154.36%↑ Y/Y)
Stock-based compensation
$816K
(206.77%↑ Y/Y)
Prepaid expenses and
other current assets
-$292K
(66.89%↑ Y/Y)
Depreciation and
amortization
$44K
(2100.00%↑ Y/Y)
Net cash used in
operating activities
-$7,504K
(34.27%↑ Y/Y)
Effect of foreign
currency translation on...
-$3K
(-105.88%↓ Y/Y)
Canceled cashflow
$1,152K
Net (loss) income
-$3,054K
(-114.84%↓ Y/Y)
Accrued expenses and
other current...
-$2,142K
(-305.68%↓ Y/Y)
Receivables
$1,767K
(499.77%↑ Y/Y)
Accounts payable
-$1,478K
(59.00%↑ Y/Y)
Change in fair value of
warrant liability
-$215K
(99.19%↑ Y/Y)
Back
Back
Cash Flow
Traws Pharma, Inc. (TRAW)
Traws Pharma, Inc. (TRAW)
source: myfinsight.com